CLINICAL TRIAL: PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QUADRIVALENT ME

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 本研究旨在评价MCV 4疫苗对脑膜炎球菌感染的安全性和有效性。 建议从11岁开始。 该疫苗的全称是四价脑膜炎球菌结合疫苗（MCV 4）。 脑膜炎球菌是一种可以引起脑膜炎的细菌。 脑膜炎是一种可能很严重甚至危及生命的疾病。 研究表明，15-24奥尔兹感染脑膜炎球菌的风险很高，艾滋病毒感染者可能比健康人感染这种病毒的风险更大。 这种疫苗不会引起脑膜炎球菌感染。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the safety and effect of MCV4 vaccine against meningococcal infections. It is recommended for people beginning at 11 years old. The full name of the vaccine is Quadrivalent Meningococcal Conjugate Vaccine (MCV4). Meningococci are bacteria that can cause Meningitis. Meningitis. is a disease that may be severe and even life threatening. Research has shown that 15-24 year olds are at high risk for infection from meningococci, and that HIV infected people may be at greater risk for this infection than healthy people. This vaccine cannot cause meningococci infection.